Dr. Kevin Lustig is the CEO of Assay Depot. Formerly, Kevin was a co-founder and the first employee of Kalypsys, a biopharma company that raised over $300 million and has multiple drug candidates in the clinic. In 2006, along with two others from Kalypsys, Kevin began what he thought would be a CRO but eventually turned into an online exchange for CROs and others. The exchange is known as Assay Depot. Kevin received his PhD from Marc Kirschner’s lab at UCSF.
Here Kevin talks about how his platform is serving as the vehicle as pharma trends more and more virtual.